natgillin/translations-raw huggingface dataset:
The clinical relevance of the waning of hSBA antibody titres against group A is unknown. 
Klinični pomen upadanja titrov protiteles hSBA proti skupini A ni znan.
Regarding waning of antibody against group A or group C after a first dose of Nimenrix in children aged 12-23 months, see under Persistence of serum bactericidal antibody titres. 
Glede upadanja protiteles proti skupini A ali C po prvem odmerku cepiva Nimenrix pri otrocih, starih od 12 do 23 mesecev, glejte Vztrajanje titrov serumskih baktericidnih protiteles, spodaj.
What Nimenrix looks like and contents of the pack 
Izgled cepiva Nimenrix in vsebina pakiranja
A new needle should be used to administer the vaccine. 
Za injiciranje cepiva je treba uporabiti novo iglo.
Appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine. 
Vedno morata biti na voljo ustrezna medicinska oskrba in nadzor za primer, da se po dajanju cepiva pojavi anafilaktična reakcija, ki pa je redka.
After a booster dose, the hSBA titres to all four serogroups were comparable between the two dosing schedules. 
Po obnovitvenem odmerku so bili titri hSBA proti vsem 4 seroskupinam primerljivi med obema shemama odmerjanja.
*tested at GSK laboratories 
* testirano v laboratorijih družbe GSK
These must be mixed together before use. 
Prašek in vehikel je treba pred uporabo zmešati skupaj.
• rash (infants). 
• izpuščaj (pri dojenčkih).
In MenACWY-TT-081, Nimenrix was demonstrated to be non-inferior to another licensed MenCCRM vaccine in terms of vaccine response to group C [94.8% (95% CI: 91.4; 97.1) and 95.7% (95% CI: 89.2; 98.8) respectively], The GMT was lower for the Nimenrix group [2795 (95% CI: 2393; 3263)] versus the MenC-CRM vaccine [5292 (95% CI: 3815; 7340)]. 
V študiji MenACWY-TT-081 se je cepivo Nimenrix izkazalo za neinferiorno drugemu odobrenemu cepivu MenC-CRM, kar zadeva odziv na skupino C [94,8 % (95 % IZ: 91,4; 97,1) in 95,7 % (95 % IZ: 89,2; 98,8) v tem zaporedju]; GMT so bile v skupini s cepivom Nimenrix nižje [2.795 (95 % IZ: 2.393; 3.263)] kot s cepivom MenC-CRM [5.292 (95 % IZ: 3.815; 7.340)].
Non-clinical data reveal no special hazard for humans based on local tolerance, acute toxicity, repeated dose toxicity, developmental/reproductive toxicity and fertility studies. 
Predklinični podatki na osnovi študij lokalnega prenašanja, akutne toksičnosti, toksičnosti pri ponavljajočih se odmerkih, razvojne/reproduktivne toksičnosti in plodnosti ne kažejo posebnega tveganja za človeka.
Intercurrent illness 
Sočasna bolezen
Infants from 6 months of age, children, adolescents and adults: a single 0.5 mL dose should be administered. 
Dojenčki, stari 6 mesecev in več, otroci, mladostniki in odrasli: uporabiti je treba en 0,5-ml odmerek.
A booster dose produced robust responses, comparable between the two dosing groups, against all four meningococcal groups. 
Obnovitveni odmerek je izzval močne odzive proti vsem 4 meningokoknim skupinam, ki so bili primerljivi med obema skupinama odmerjanja.
Nimenrix should under no circumstances be administered intravascularly, intradermally or subcutaneously. 
Cepiva Nimenrix se nikakor ne sme dajati intravaskularno, intradermalno ali subkutano.
In a separate study (MenACWY-TT-085) a single dose of Nimenrix was administered to 194 Lebanese adults 56 years of age and older (including 133 aged 56-65 years and 61 aged > 65 years). 
V ločeni študiji (MenACWY-TT-085) je en odmerek cepiva Nimenrix prejelo 194 odraslih Libanoncev, starih 56 let ali več (od tega jih je bilo 133 starih od 56 do 65 let in 61 starih > 65 let).
*rSBA testing performed at Public Health England (PHE) laboratories in UK **hSBA tested at GSK laboratories (1) blood sampling performed 21 to 48 days post vaccination Data from MenACWY-TT-083 support the extrapolation of the immunogenicity data and posology to infants from 12 weeks to less than 6 months of age. 
* testiranje rSBA so opravili v laboratorijih PHE (Public Health England) v Veliki Britaniji ** hSBA so testirali v laboratorijih družbe GSK odvzem krvi so opravili od 21 do 48 dni po cepljenju Podatki iz študije MenACWY-TT-083 podpirajo ekstrapolacijo podatkov o imunogenosti in odmerjanja na dojenčke, stare od 12 tednov do manj kot 6 mesecev.
*rSBA testing performed at PHE laboratories in UK. 
*testiranje rSBA so opravili v laboratorijih PHE v Veliki Britaniji
In infants, the recommended injection site is the anterolateral aspect of the thigh. 
Pri dojenčkih je priporočeno mesto injiciranja anterolateralni predel stegna.
After reconstitution, use promptly. 
Uporabite takoj po rekonstituciji.
After the addition of the solvent to the powder, the mixture should be well shaken until the powder is completely dissolved in the solvent. 
Po dodatku vehikla prašku je treba mešanico dobro pretresti, dokler se prašek povsem ne raztopi v vehiklu.
Although an increase of the anti-tetanus toxoid (TT) antibody concentrations was observed following vaccination with Nimenrix, Nimenrix does not substitute for tetanus immunisation. 
Po cepljenju s cepivom Nimenrix so sicer opažali porast koncentracije protiteles proti tetanusnemu toksoidu (TT), vendar cepivo Nimenrix ne nadomešča imunizacije proti tetanusu.
Persistence of serum bactericidal antibody titres 
Vztrajanje titrov serumskih baktericidnih protiteles
EU/1/12/767/001 - pack of 1 without needle EU/1/12/767/002 - pack of 10 without needle EU/1/12/767/003 - pack of 1 with 2 needles EU/1/12/767/004 - pack of 10 with 20 needles 
EU/1/12/767/001 - pakiranje po 1 brez igle EU/1/12/767/002 - pakiranje po 10 brez igle EU/1/12/767/003 - pakiranje po 1 in 2 iglama EU/1/12/767/004 - pakiranje po 10 in 20 iglami
Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y. 
Cepivo Nimenrix je indicirano za aktivno imunizacijo posameznikov starejših od 6 tednov proti invazivnim meningokoknim boleznim, ki jih povzroča Neisseria meningitidis skupin A, C, W-135 in Y.
There was no impact of co-administration on immune responses to Nimenrix or the tetanus or diphtheria antigens included in Tdap. 
Sočasna uporaba ni vplivala na imunske odzive na cepivo Nimenrix ali na antigene tetanusa ali davice, ki jih vsebuje cepivo Tdap.
In MenACWY-TT-038, Nimenrix was demonstrated to be non-inferior to the licensed ACWY-PS vaccine in terms of vaccine response to the four groups (A, C, W-135 and Y) (See Table 9). 
V študiji MenACWY-TT-038 se je cepivo Nimenrix izkazalo za neinferiorno odobrenemu cepivu ACWY-PS, kar zadeva odziv na štiri skupine (A, C, W-135 in Y) po cepljenju (glejte preglednico 9).
Other medicines and Nimenrix 
Druga zdravila in cepivo Nimenrix
Break the top of the ampoule, draw up the solvent with a syringe and add the solvent to the powder. 
Odlomite vrh ampule, z brizgo izvlecite vehikel in dodajte vehikel k prašku.
DTaP-HBV-IPV/Hib and a 10-valent pneumococcal vaccine were co-administered. 
Cepivo DTaP-HBV-IPV/Hib in 10-valentno pnevmokokno cepivo so dajali sočasno.
Two clinical studies have been conducted in infants, MenACWY-TT-083 and MenACWY-TT-087. 
Pri dojenčkih so opravili 2 klinični študiji, in sicer študiji MenACWY-TT-083 in MenACWY-TT-087.
*rSBA testing performed at PHE laboratories in UK ** tested at GSK laboratories 
* testiranje rSBA so opravili v laboratorijih PHE v Veliki Britaniji ** testirano v laboratorijih družbe GSK
The following information is intended for healthcare professionals only: The vaccine is for intramuscular use only. 
Naslednje informacije so namenjene samo zdravstvenemu osebju:
Very common (these may occur with more than 1 in 10 doses of the vaccine): 
Zelo pogosti (pojavijo se lahko pri več kot 1 na 10 odmerkov cepiva):
A single primary dose administered at 6 months of age elicited robust rSBA responses to groups A, C, W-135 and Y, as measured by the percentage of subjects with rSBA titres ≥8, that were comparable to responses after the last dose of a three-dose primary series. 
Enkratni osnovni odmerek, ki so ga dali pri starosti 6 mesecev, je izzval močne odzive rSBA proti skupinam A, C, W-135 in Y, merjeno z odstotkom preskušancev s titri rSBA ≥ 8, ki so bili primerljivi z odzivi po zadnjem odmerku iz osnovne sheme 3 odmerkov.
Add the solvent to the powder. 
Prašku dodajte vehikel.
A single dose was associated with lower hSBA titres to groups W-135 and Y compared with two doses given two months apart. 
Pri hSBA je bil enkratni odmerek povezan z nižjimi titri proti skupinama W-135 in Y v primerjavi z dvema odmerkoma, danima v presledku 2 mesecev.
Nimenrix elicited a bactericidal antibody response against the four meningococcal groups. 
Cepivo Nimenrix je povzročilo odziv baktericidnih protiteles na štiri meningokokne skupine.
In MenACWY-TT-087, infants received either a single primary dose at 6 months followed by a booster dose at 15-18 months (DTPa-IPV/Hib and 10-valent pneumococcal conjugate vaccine was co-administered at both vaccination time points) or three primary doses at 2, 4, and 6 months followed by a booster dose at 15-18 months. 
V študiji MenACWY-TT-087 so dojenčki prejeli bodisi 1 osnovni odmerek pri 6 mesecih, ki mu je sledil obnovitveni odmerek pri 15-18 mesecih (DTPa-IPV/Hib in 10-valentno pnevmokokno konjugirano cepivo so dali sočasno v obeh časovnih točkah cepljenja), bodisi 3 osnovne odmerke pri 2, 4 in 6 mesecih, ki jim je sledil obnovitveni odmerek pri 15-18 mesecih.
Bactericidal antibody responses in infants 6 months of age measured one month after a single primary dose, prior to a booster dose, and one month after a booster dose are presented in Table 3. 
Odzivi baktericidnih protiteles pri dojenčkih, starih 6 mesecev, izmerjeni 1 mesec po enkratnem osnovnem odmerku, pred obnovitvenim odmerkom in 1 mesec po obnovitvenem odmerku, so navedeni v preglednici 3.
The percentage of subjects with rSBA titres (measured at GSK's laboratories) ≥128 before vaccination ranged from 45% (group C) to 62% (group Y). 
Delež oseb s titri rSBA (izmerjeni v laboratorijih družbe GSK) ≥ 128 pred cepljenjem je znašal od 45 % (skupina C) do 62 % (skupina Y).
What Nimenrix is and what it is used for What you need to know before you receive Nimenrix How Nimenrix is given 
Kaj je cepivo Nimenrix in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli cepivo Nimenrix Kako se daje cepivo Nimenrix Možni neželeni učinki
After reconstitution, 1 dose (0.5 ml) contains 5 micrograms of Neisseria meningitidis group A, C, W135 and Y polysaccharides. 
Po rekonstituciji vsebuje 1 odmerek (0,5 ml) 5 mikrogramov polisaharidov Neisseria meningitidis skupin A, C, W-135 in Y.
Infants from 6 weeks to less than 6 months of age Two injections given 2 months apart at e.g. 2 and 4 months of age (the first injection may be given from the age of 6 weeks). 
Dve injekciji v presledku 2 mesecev, npr. pri starosti 2 in 4 mesecev (prvo injekcijo lahko prejme pri starosti od 6 tednov dalje).
Diarrhoea Vomiting Nausea* 
Bolezni prebavil pogosti diareja bruhanje navzea*
Nimenrix elicited bactericidal responses against all four groups that were similar in terms of % with rSBA titre ≥8 and GMT after one or two doses (Table 6). 
Cepivo Nimenrix je povzročilo baktericidne odzive proti vsem štirim skupinam, ki so bili (kar zadeva odstotke s titri rSBA ≥ 8 in GMT) podobni po enem ali dveh odmerkih (preglednica 6).
• aching muscles 
• boleče mišice
In clinical studies MenACWY-TT-039 and MenACWY-TT-040 a single dose of Nimenrix elicited rSBA responses against the four meningococcal groups, with a response against group C that was comparable to the one elicited by the licensed MenC-CRM vaccine in terms of percentages with rSBA 
V kliničnih študijah MenACWY-TT-039 in MenACWY-TT-040 je en odmerek cepiva Nimenrix povzročil odzive rSBA proti štirim meningokoknim skupinam; odziv proti skupini C je bil (kar zadeva odstotke s titri rSBA ≥ 8) primerljiv odzivu na odobreno cepivo MenC-CRM (preglednica 4).
To attach the needle to the syringe, refer to the below picture. 
Za namestitev igle na brizgo glejte spodnjo sliko.
Previously vaccinated individuals 12 months of age and older: Please tell your doctor if you have received a previous injection with another meningococcal vaccine than Nimenrix.Your doctor will tell you if and when you need an additional dose of Nimenrix, especially if you or your child: 
Obvestite zdravnika, če ste bili predhodno cepljeni z drugim meningokoknim cepivom kot je cepivo Nimenrix.Zdravnik vam bo povedal, če potrebujete dodaten odmerek cepiva Nimenrix, zlasti če ste vi ali vaš otrok:
In MenACWY-TT-083, the first dose was administered at 6 to 12 weeks of age, the second dose was given after an interval of 2 months and a third (booster) dose was given at the age of approximately 12 months. 
V študiji MenACWY-TT-083 so jim prvi odmerek dali pri starosti od 6 do 12 tednov, drugi odmerek 2 meseca po prvem odmerku in tretji (obnovitveni) odmerek pri starosti približno 12 mesecev.
titre ≥8) was observed against all groups (A, C, W-135, Y) in all subjects regardless of the meningococcal vaccine history. 
Imunski odziv (titer rSBA ≥ 8) so zabeležili za vse skupine (A, C, W-135, Y) pri vseh preskušancih, ne glede na njihovo anamnezo cepiv proti meningokokom.
After completion of the primary immunisation course in infants 6 weeks to less than 12 months of age, a booster dose should be given at 12 months of age with an interval of at least 2 months after the last Nimenrix vaccination (see section 5.1). 
Po končani osnovni imunizaciji pri dojenčkih, starih od 6 tednov do manj kot 12 mesecev, jim je treba pri starosti 12 mesecev dati obnovitveni odmerek, od zadnjega cepljenja s cepivom Nimenrix pa morata miniti najmanj 2 meseca (glejte poglavje 5.1).
The local and general adverse reaction profile of a booster dose of Nimenrix given to subjects from 12 months through 30 years of age after primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines, was similar to the local and general adverse reaction profile observed after primary vaccination with Nimenrix, except for gastrointestinal symptoms (including diarrhoea, vomiting, and nausea), which were very common among subjects 6 years of age and older. 
Profil lokalnih in splošnih neželenih učinkov obnovitvenega odmerka cepiva Nimenrix, ki so ga prejeli preskušanci, stari od 12 mesecev do 30 let, po osnovnem cepljenju s cepivom Nimenrix ali drugimi konjugiranimi ali navadnimi polisaharidnimi meningokoknimi cepivi, je bil podoben profilu lokalnih in splošnih neželenih učinkov, opaženem po osnovnem cepljenju s cepivom Nimenrix, razen gastrointestinalnih simptomov (vključno z diarejo, bruhanjem in navzeo), ki so bili pri preskušancih, starih 6 let in več, zelo pogosti.
One month after co-administration with a 10-valent pneumococcal conjugate vaccine, lower Geometric Mean antibody Concentrations (GMCs) and opsonophagocytic assay (OPA) antibody GMTs were observed for one pneumococcal serotype (18C conjugated to tetanus toxoid carrier protein). 
En mesec po sočasni uporabi z 10-valentnim konjugiranim pnevmokoknim cepivom so ugotovili nižje geometrične sredine koncentracije protiteles (GMC - Geometric Mean antibody Concentration) in nižje z opsonofagocitnim preskusom (OPA - OpsonoPhagocytic Assay) določene GMT protiteles proti enemu pnevmokoknemu serotipu (18C konjugiran na nosilno beljakovino tetanusnega toksoida).
The mixture should be well shaken until the powder is completely dissolved in the solvent. 
Mešanico dobro pretresite, dokler se prašek popolnoma ne raztopi v vehiklu.
If an infant aged 6 months to less than 12 months of age is expected to be at particular risk of invasive meningococcal disease due to exposure to groups W-135 and Y, consideration may be given to administering a second primary dose of Nimenrix after an interval of 2 months. 
Če pri dojenčku, starem od 6 mesecev do manj kot 12 mesecev, pričakujemo posebej veliko tveganje za invazivno meningokokno bolezen zaradi izpostavljenosti skupinama W-135 in Y, lahko razmislimo o uporabi drugega osnovnega odmerka cepiva Nimenrix v razmiku 2 mesecev po prvem odmerku.
Name and address of the manufacturers of the biological active substance GlaxoSmithKline Biologicals S.A. 
Ime in naslov izdelovalcev biološke učinkovine GlaxoSmithKline Biologicals S.A. 89, rue de l'Institut
• Data from a study in infants aged 6 to 12 weeks at the time of the first dose (Study MenACWY-TT-083), 1,052 subjects received at least one dose of a primary series of 2 or 3 doses of Nimenrix and 1,008 received a booster dose at approximately 12 months of age. 
• Podatki iz študije pri dojenčkih, ki so bili v času prvega odmerka stari od 6 do 12 tednov (Študija MenACWY-TT-083), v kateri je vsaj en odmerek iz osnovne sheme 2 ali 3 odmerkov cepiva Nimenrix prejelo 1.052 preskušancev, 1.008 pa jih je prejelo obnovitveni odmerek pri približno 12 mesecih starosti.
Immune response in infants aged 6 months to less than 12 months A single dose administered at 6 months was associated with lower human complement serum bactericidal assay (hSBA) titres to groups W-135 and Y compared with three doses administered at 2, 4, and 6 months (see section 5.1). 
Imunski odziv pri dojenčkih, starih od 6 mesecev do manj kot 12 mesecev V preskusu baktericidnosti v serumu s humanim komplementom (hSBA - human complement Serum Bactericidal Assay) je bil enkratni odmerek, ki so ga dali pri starosti 6 mesecev, povezan z nižjimi titri proti skupinama W-135 in Y v primerjavi s 3 odmerki, ki so jih dali pri starosti 2, 4 in 6 mesecev (glejte poglavje 5.1).
Infants from 6 weeks to less than 6 months of age: two doses, each of 0.5 ml, should be administered with an interval of 2 months between doses. 
Dojenčki, stari od 6 tednov do manj kot 6 mesecev: uporabiti je treba 2 odmerka po 0,5 ml, med katerima morata miniti 2 meseca.
If you are not sure, talk to your doctor or nurse before you receive Nimenrix. 
Če ste negotovi, se posvetujte z zdravnikom ali medicinsko sestro, preden dobite cepivo Nimenrix.
1 month post-vaccination (study MenACWY-TT-027) 
1 mesec po cepljenju (študija MenACWY-TT-027)
Effect of prior vaccination with plain polysaccharide meningococcal vaccine Subjects previously vaccinated with a plain polysaccharide meningococcal vaccine and vaccinated with Nimenrix 30 to 42 months later had lower Geometric Mean Titres (GMTs) measured with a serum bactericidal assay using rabbit complement (rSBA) than subjects who had not been vaccinated with any meningococcal vaccine in the preceding 10 years (see section 5.1). 
Vpliv predhodnega cepljenja z navadnim polisaharidnim meningokoknim cepivom Osebe, predhodno cepljene z navadnim polisaharidnim meningokoknim cepivom, od 30 do 42 mesecev pozneje pa s cepivom Nimenrix, so imele nižje geometrične sredine titrov (GMTGeometric Mean Titre), določene s preskusom baktericidnosti v serumu s kunčjim komplementom (rSBA - rabbit complement Serum Bactericidal Assay), kot osebe, ki v zadnjih 10 letih niso prejele nobenega cepiva proti meningokokom (glejte poglavje 5.1).
In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus bivalent [Type 16 and 18] vaccine, recombinant (HPV2). 
Pri posameznikih, starih od 9 do 25 let, lahko cepivo Nimenrix dajemo sočasno z 2-valentnim rekombinantnim cepivom proti humanim papiloma virusom [tipa 16 in 18] (HPV2).
In study MenACWY-TT-021 conducted in subjects aged 4.5-34 years, the immunogenicity of Nimenrix administered between 30 and 42 months after vaccination with a ACWY-PS vaccine was compared to the immunogenicity of Nimenrix administered to age-matched subjects who had not been vaccinated with any meningococcal vaccine in the preceding 10 years. 
V študiji MenACWY-TT-021 (opravljeni pri preskušancih, starih od 4,5 do 34 let) so imunogenost cepiva Nimenrix, uporabljenega od 30 do 42 mesecev po cepljenju s cepivom ACWY-PS, primerjali z imunogenostjo cepiva Nimenrix, danega enako starim preskušancem, ki v 10 letih pred tem niso prejeli nobenega cepiva proti meningokokom.
In infants, Nimenrix can be given concomitantly with combined DTaP-HBV-IPV/Hib vaccines and with 10-valent pneumococcal conjugate vaccine. 
Pri dojenčkih lahko cepivo Nimenrix dajemo sočasno s kombiniranimi cepivi DTaP-HBV-IPV/Hib in 10-valentnim konjugiranim pnevmokoknim cepivom.
Y 723 
A 743
In individuals aged 9 to 25 years, Nimenrix can be given concomitantly with human papillomavirus vaccine [Types 16, 18] and a combined diphtheria (reduced antigen content), tetanus and acellular pertussis vaccine. 
Pri posameznikih, starih od 9 do 25 let, lahko cepivo Nimenrix dajemo sočasno s cepivom proti humanim papiloma virusom [tipa 16 in 18] ter kombiniranim cepivom proti davici (z zmanjšano vsebnostjo antigenov), tetanusu in oslovskemu kašlju (acelularno).
ACWY-PS vaccine 
Nimenrix cepivo ACWY-PS
Table 14: 1 month post-vaccination (Study MenACWY-TT-052) and 5 years (Study MenACWY-TT-059) persistence data (hSBA*) in adolescents and adults 11-25 years of age 
Preglednica 14: Podatki 1 mesec po cepljenju (študija MenACWY-TT-052) in o trajanju imunskega odziva (hSBA*) 5 let po cepljenju (študija MenACWY-TT-059) pri mladostnikih in odraslih, starih od 11 do 25 let
Extensive limb swelling at the injection site, frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb *Nausea and Injection site haematoma occurred at a frequency of Uncommon in infants **Rash occurred at a frequency of Common in infants ***ADR identified post-marketing 
občasni splošno slabo počutje zatrdlina na mestu injiciranja srbenje na mestu injiciranja toplota na mestu injiciranja anestezija na mestu injiciranja neznana*** obsežna oteklina okončine na mestu injiciranja, ki včasih zajame sosednji sklep in je pogosto povezana z eritemom ali oteklina celotne okončine v katero je bilo injicirano cepivo * pri dojenčkih sta se navzea in hematom na mestu injiciranja pojavljala s pogostnostjo ''občasni'' ** pri dojenčkih se je izpuščaj pojavljal s pogostnostjo ''pogosti'' *** neželeni učinki, ugotovljeni v obdobju trženja cepiva
Immunogenicity in toddlers aged 12-23 months 
Imunogenost pri malčkih, starih od 12 do 23 mesecev
The rSBA GMTs were significantly lower in the subjects who had received a dose of ACWY-PS vaccine 30-42 months prior to Nimenrix, however 100% of subjects achieved rSBA titers ≥8 for all four meningococcal groups (A, C, W-135, Y) (see section 4.4). 
Pri preskušancih, ki so prejeli odmerek cepiva ACWY-PS 30 do 42 mesecev pred cepivom Nimenrix, so opazili signifikantno nižje GMT rSBA, vendar pa je kljub temu 100 % preskušancev doseglo titre rSBA ≥ 8 za vse štiri meningokokne skupine (A, C, W-135, Y) (glejte poglavje 4.4).
Whenever possible, Nimenrix and a TT containing vaccine, such as DTaP-HBV-IPV/Hib vaccine, should be co-administered or Nimenrix should be administered at least one month before the TT containing vaccine. 
Kadar je le mogoče, je treba cepivo Nimenrix in cepivo s TT, npr. cepivo DTaP-HBV-IPV/Hib, dati hkrati, ali pa je treba cepivo Nimenrix dati vsaj en mesec pred cepivom s TT.
• The active substances are: - After reconstitution, 1 dose (0.5 ml) contains: Neisseria meningitidis group A polysaccharide1 
• Učinkovine so: - Po rekonstituciji vsebuje 1 odmerek (0,5 ml): Polisaharid Neisseria meningitidis skupine A
The administration of Nimenrix one month after the DTaP-HBV-IPV/Hib vaccine resulted in lower rSBA GMTs against groups A, C and W-135 compared with co-administration (see section 4.5). 
Z uporabo cepiva Nimenrix en mesec po cepivu DTaP-HBV-IPV/Hib so bile dosežene nižje GMT rSBA proti skupinam A, C in W-135 v primerjavi s sočasno uporabo (glejte poglavje 4.5).
Nimenrix must be reconstituted by adding the entire content of the pre-filled syringe of solvent to the vial containing the powder. 
Cepivo Nimenrix je treba rekonstituirati tako, da se celotno vsebino napolnjene injekcijske brizge z vehiklom doda v vialo s praškom.